Measurable residual disease in the treatment of chronic lymphocytic leukemia

Treatment outcomes of chronic lymphocytic leukemia (CLL) have improved since chemoimmunotherapy and novel drugs became available for CLL treatment; therefore, more sensitive methods to evaluate residual CLL cells in patients are required. Measurable residual disease (MRD) has been assessed in severa...

Descripción completa

Detalles Bibliográficos
Autores principales: Uchiyama, Takayoshi, Yokoyama, Aki, Aoki, Sadao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Japanese Society for Lymphoreticular Tissue Research 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7810249/
https://www.ncbi.nlm.nih.gov/pubmed/33148932
http://dx.doi.org/10.3960/jslrt.20014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7810249/
https://www.ncbi.nlm.nih.gov/pubmed/33148932
http://dx.doi.org/10.3960/jslrt.20014

Ejemplares similares